CYP2C18 Inhibitors

CYP2C18 inhibitors primarily function by binding to the active site of the enzyme or altering its structure, thus preventing it from metabolizing its substrates. The inhibition of CYP2C18 can have significant pharmacological implications, as it can affect the metabolism of compounds processed by this enzyme. Ketoconazole and other antifungal agents like Fluconazole, Miconazole, Itraconazole, and Voriconazole are known for their broad-spectrum inhibition of Cytochrome P450 enzymes. These compounds bind to the heme group of the CYP450 enzymes, thereby inhibiting their catalytic activity. This can lead to reduced metabolism of compounds and other substances that are substrates of these enzymes, including the retinoids metabolized by CYP2C18. Sulfaphenazole, while more specific to CYP2C9, can also inhibit other CYP2C family members. It acts as a competitive inhibitor, occupying the active site of the enzyme and preventing substrate binding. Quinidine and Amiodarone, as antiarrhythmic chemicals, inhibit multiple CYP enzymes, including CYP2C18. This inhibition can affect the metabolism of various compound, leading to altered pharmacokinetic profiles.

Clopidogrel and Ticlopidine are antiplatelet compounds that have been observed to inhibit CYP2C18. Their inhibition can increase the plasma concentration of drugs metabolized by CYP2C18, potentially leading to chemcial interactions. Montelukast, a leukotriene receptor antagonist, has shown inhibitory effects on CYP2C8 and potentially affects CYP2C18. This can influence the metabolism of substances that are substrates of these enzymes. Phenylbutazone, an NSAID, is known to inhibit several CYP enzymes. It can decrease the metabolic activity of CYP2C18, affecting compound metabolism and clearance. The inhibition of CYP2C18 can have important implications in chemical interactions and metabolism. Compounds that inhibit CYP2C18 can lead to increased plasma levels of its substrates, potentially resulting in toxicity or enhanced effects.